Jiangsu Hengrui Pharmaceuticals (01276): HRS-1597 tablets have obtained the Drug Clinical Trial Approval Notice.
Hengrui Medicine (01276) announced that recently, its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) for HRS-1597 tablets, and will soon initiate clinical trials.
Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the Clinical Trial Approval Notice for HRS-1597 tablets issued by the National Medical Products Administration (NMPA), and will soon commence clinical trials.
Related Articles
BIOSYSEN (01355): 256 million unsubscribed rights issue shares have been successfully allocated.
BOAN BIOTECH (06955) spent HKD 5.237 million on September 7 to repurchase 1.7 million shares.
CENTRALCHINA MT(09982): Liu Lin resigns as the company's executive director.
BIOSYSEN (01355): 256 million unsubscribed rights issue shares have been successfully allocated.
BOAN BIOTECH (06955) spent HKD 5.237 million on September 7 to repurchase 1.7 million shares.
CENTRALCHINA MT(09982): Liu Lin resigns as the company's executive director.
RECOMMEND
